Rétinite virale secondaire à une injection intravitréenne de triamcinolone

Zghal, I.; Malek, Ines; Amel, C; Soumaya, O; Bouguila, Hajer; Nacef, L.

doi:10.1016/j.jfo.2012.08.015

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, visual outcomes are good after treating the eye acutely as if it was infectious endophthalmitis [83]. Other recently reported, though rare, side effects of intravitreal injection of triamcinolone include persistence of crystals on the surface of the retina for multiple years resembling crystalline retinopathy [84], reactivation of viral retinitis [85], intraocular hemorrhage, retinal detachment, and fulminant toxoplasmic retinochoroiditis [86].…”

Section: Triamcinolone Acetonidementioning

confidence: 99%

Corticosteroids for the Treatment of Diabetic Macular Edema

Sharma

Mruthyunjaya

2014

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Diabetic macular edema (DME) is a leading cause of vision loss throughout the world. Three different corticosteroids have been used in the treatment of diabetic macular edema: triamcinolone acetonide, dexamethasone, and fluocinolone acetonide. Intravitreal injection of all three corticosteroids is associated with a similar side effect profile including worsening/formation of cataract, elevation of intraocular pressure, pseudo-endophthalmitis, and infectious endophthalmitis. Sustained-release implants of corticosteroids have recently been studied, and one has recently received FDA approval as the first corticosteroid for the treatment of diabetic macular edema. This review will address some of the major studies evaluating corticosteroids for DME and will focus on studies published within the last 2 years.

show abstract

Section: Triamcinolone Acetonidementioning

confidence: 99%

Corticosteroids for the Treatment of Diabetic Macular Edema

Sharma

Mruthyunjaya

2014

Curr Ophthalmol Rep

View full text Add to dashboard Cite

show abstract

Cytomegalovirus Anterior Uveitis

Jap

2017

Emerging Infectious Uveitis

View full text Add to dashboard Cite

Pars Plana Vitrectomy With Internal Limiting Membrane Peeling for the Treatment of Cystoid Macular Edema in a Patient With Syphilitic Uveitis and HIV Infection

Pappaterra-Rodriguez¹,

Amaral²,

Figueroa³

et al. 2022

Cureus

View full text Add to dashboard Cite

We report a case of cystoid macular edema (CME) secondary to syphilitic uveitis that was successfully treated with pars plana vitrectomy with internal limiting membrane peeling. A 37-year-old male with a history of HIV developed a CME secondary to syphilitic panuveitis. His uveitis resolved following treatment with intravenous penicillin, yet his CME persisted and was refractory to four posterior sub-tenon triamcinolone acetonide injections. A pars plana vitrectomy with internal limiting membrane peeling was performed, resulting in lasting resolution of the CME and the improvement of his visual acuity at the twomonth follow-up visit. Pars plana vitrectomy with internal limiting membrane peeling may be a viable alternative for the treatment of CME in patients with syphilitic uveitis. In particular, it may serve as a viable alternative for the treatment of CME in patients with a history of infectious uveitis or other comorbidities, such as HIV infection.

show abstract

Rétinite virale secondaire à une injection intravitréenne de triamcinolone

Cited by 3 publications

References 16 publications

Corticosteroids for the Treatment of Diabetic Macular Edema

Corticosteroids for the Treatment of Diabetic Macular Edema

Cytomegalovirus Anterior Uveitis

Pars Plana Vitrectomy With Internal Limiting Membrane Peeling for the Treatment of Cystoid Macular Edema in a Patient With Syphilitic Uveitis and HIV Infection

Contact Info

Product

Resources

About